1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis - Drugs In Development, 2022, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 17, 46, 29, 5, 178, 80 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 38 and 14 molecules, respectively.
Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Amyotrophic Lateral Sclerosis - Overview
- Amyotrophic Lateral Sclerosis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Amyotrophic Lateral Sclerosis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
- Amyotrophic Lateral Sclerosis - Drug Profiles
- Amyotrophic Lateral Sclerosis - Dormant Projects
- Amyotrophic Lateral Sclerosis - Discontinued Products
- Amyotrophic Lateral Sclerosis - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Amyotrophic Lateral Sclerosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Amyotrophic Lateral Sclerosis - Dormant Projects, 2022
- Amyotrophic Lateral Sclerosis - Discontinued Products, 2022
- Number of Products under Development for Amyotrophic Lateral Sclerosis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1st Bio Therapeutics Inc
- 2N Pharma ApS
- 4B Technologies (Suzhou) Co Ltd
- 4P-Pharma SAS
- AB Science SA
- Abbisko Cayman Limited
- Above and Beyond Concierge Therapeutics LLC
- AC Immune SA
- Aclipse One Inc
- Aclipse Therapeutics LLC
- Actimed Therapeutics Ltd
- AcuraStem Inc
- Adare Pharma Solutions
- Aeterna Zentaris Inc
- AgoneX Biopharmaceuticals Inc
- AI Therapeutics Inc
- AL-S Pharma AG
- Alector Inc
- Alexion Pharmaceuticals Inc
- Allife Medical Science and Technology Co Ltd
- Alnylam Pharmaceuticals Inc
- AlphaCognition Inc
- Alsonex Pty Ltd
- Amarna Therapeutics BV
- Amicogen Inc
- Amplo Biotechnology Inc
- Amylyx Pharmaceuticals Inc
- Anima Biotech Inc
- Ankar Pharma SL
- ANLBio Co Ltd
- Annexon Inc
- Apellis Pharmaceuticals Inc
- Apic Bio Inc
- Apogenix AG
- Applied Genetic Technologies Corp
- Aquilus Pharmaceuticals Inc
- Aquinnah Pharmaceuticals Inc
- AriBio
- ArmaGen Inc
- ArunA Bio Inc
- Asahi Kasei Pharma Corp
- Asdera LLC
- Asha Therapeutics LLC
- Ashvattha Therapeutics LLC
- Astellas Pharma Inc
- Astrogen Ltd
- Athira Pharma Inc
- Autotac Bio Inc
- Avanir Pharmaceuticals Inc
- AviadoBio Ltd
- Avrion Therapeutics AG
- BenevolentAI Ltd
- BioArctic AB
- Bioasis Technologies Inc
- Biogen Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Bioleaders Corp
- Biolexis Therapeutics Inc
- Biorchestra Co Ltd
- Bisichem Co Ltd
- Bloom Science Inc
- BrainEver SAS
- BrainStorm Cell Therapeutics Inc
- Bruschettini Srl
- Calico Life Sciences LLC
- Capsida Biotherapeutics Inc
- CavoGene LifeSciences
- CellCure
- Cellenkos Inc
- Ceptur Therapeutics Inc
- Cerion LLC
- Chaperone Therapeutics Inc
- Chemigen LLC
- Chiesi Farmaceutici SpA
- CholesteniX Ltd
- Chronos Therapeutics Ltd
- Clene Inc
- Clevexel Pharma SA
- Clinigen Ltd
- Coave Therapeutics
- Codiak BioSciences Inc
- Cogentis Therapeutics Inc
- Collaborative Medicinal Development LLC
- Constant Therapeutics LLC
- Corcept Therapeutics Inc
- Corestem Inc
- Coya Therapeutics Inc
- Curatis AG
- CuroNZ Ltd
- Cytokinetics Inc
- Daiichi Sankyo Co Ltd
- Deargen Inc
- Denali Therapeutics Inc
- Dewpoint Therapeutics Inc
- Disarm Therapeutics Inc
- DR.Noah Biotech Inc
- Eikonizo Therapeutics Inc
- Eikonoklastes Therapeutics Inc
- Eisai Co Ltd
- Eledon Pharmaceuticals Inc
- Eli Lilly and Co
- Elixiron Immunotherapeutics Inc
- Elysium Health Inc
- EmendoBio Inc
- Emerald Health Sciences Inc
- ENCEFA
- Enveda Biosciences Inc
- Enzerna Biosciences LLC
- Eolo Pharma
- Everfront Biotech Inc
- Exicure Inc
- Expansion Therapeutics Inc
- Expesicor Inc
- Faze medicines
- Foshan Rexie Biotechnology Co Ltd
- Gene Therapy Research Institution Co Ltd
- Generoath Co Ltd
- Genervon Biopharmaceuticals LLC
- Genetic Intelligence Inc
- GeNeuro SA
- Genuv Inc
- Glialogix Inc
- GlyTag LLC
- GNT Pharma Co Ltd
- Grifols SA
- Grupo Ferrer Internacional SA
- Guangzhou Magpie Pharmaceutical Co Ltd
- Helixmith Co Ltd
- Hemostemix Inc
- Herantis Pharma Plc
- Hope Biosciences LLC
- Hopstem Biotechnology LLC
- Iltoo Pharma
- Immunity Pharma Ltd
- ImmunoBrain Checkpoint Inc
- ImmunoForge Co Ltd
- Implicit Bioscience Ltd
- ImStar Therapeutics Inc
- InFlectis BioScience SAS
- Inmune Bio Inc
- InnoMedica Holding AG
- InnoPharmaScreen Inc
- Io Therapeutics Inc
- Ionis Pharmaceuticals Inc
- Iron Horse Therapeutics Inc
- Jiangsu Ouwei Pharmaceutical Co Ltd
- Junaxo Inc
- Jupiter Neurosciences Inc
- K Pharma Inc
- K-Pax Pharmaceuticals Inc
- Kadimastem Ltd
- Keapstone Therapeutics Ltd
- KeifeRx LLC
- Klogene Therapeutics Inc
- Knopp Biosciences LLC
- Kringle Pharma Inc
- Kyorin Pharmaceutical Co Ltd
- Lascco SA
- Lauren Sciences LLC
- LifeSplice Pharma LLC
- Locanabio Inc
- Longboard Pharmaceuticals Inc
- Maas Biolab
- Maze Therapeutics Inc
- MD Healthcare Inc
- MedDay SA
- MeiraGTx Holdings Plc
- Merck & Co Inc
- MetrioPharm AG
- MetVital Inc
- MimeTech Srl
- Mitochon Pharmaceuticals Inc
- Mitochondria In Motion Inc
- Mitoconix Bio Ltd
- MitoDys Therapeutics Ltd
- Mitsubishi Tanabe Pharma Corp
- NeuExcell Therapeutics Inc
- Neugen Pharma Inc
- Neuracle Genetics Inc
- Neuracle Science Co Ltd
- Neurevo GmbH
- Neurimmune Holding AG
- Neurodegeneration Therapeutics Inc
- NeuroGenesis Ltd
- Neuromagen Pharma Ltd
- Neuropath Therapeutics Ltd
- Neuroplast BV
- Neuropore Therapies Inc
- NeuroSense Therapeutics Ltd
- Neurotune AG
- Neuvivo Inc
- Nevrox Ltd
- New Biotic Inc
- Newron Pharmaceuticals SpA
- Nine Square Therapeutics Inc
- Nobelpharma Co Ltd
- Novartis AG
- Novartis Gene Therapies
- NovelMed Therapeutics Inc
- NuNerve Pty Ltd
- NysnoBio LLC
- Oncocross Co Ltd
- OptiKira LLC
- Orchard Therapeutics Plc
- Origami Therapeutics Inc
- Orpheris Inc
- Palisade Bio, Inc
- Parnia Stem Cell Knowledge-Based Co
- Pasithea Therapeutics Corp
- Passage Bio Inc
- Pfizer Inc
- PharmaTher Holdings Ltd
- PharmAust Ltd
- PharmEnable Ltd
- Pharnext SA
- Plex Pharmaceuticals Inc
- PRG S&Tech Inc
- Priavoid GmbH
- Prilenia Therapeutics Development Ltd
- Projenx Inc
- ProMIS Neurosciences Inc
- Prosetta Biosciences Inc
- Prothena Corp Plc
- Prous Institute for Biomedical Research SA
- PTC Therapeutics Inc
- PurMinds NeuroPharma Inc
- Q Therapeutics Inc
- Q-State Biosciences Inc
- QurAlis Corporation
- Ra Pharmaceuticals Inc
- Rapa Therapeutics LLC
- RASRx LLC
- Reata Pharmaceuticals Inc
- ReceptoPharm Inc
- Regulus Therapeutics Inc
- reMYND NV
- ReoStem LLC
- ResQ Biotech
- Retrotope Inc
- Revalesio Corp
- Sangamo Therapeutics Inc
- SciNeuro Pharmaceuticals
- Seelos Therapeutics, Inc.
- Shanghai Pharmaceuticals Holding Co Ltd
- Shanghai Zhimeng Biopharma Inc
- Shinkei Therapeutics LLC
- Sio Gene Therapies Inc
- SOLA Biosciences LLC
- Spedding Research Solutions SAS
- Spinogenix Inc
- Stealth BioTherapeutics Corp
- Suzhou Auzone Biological Technology Co Ltd
- Symbinas Pharmaceuticals Inc
- Takara Bio Inc
- Talon Pharmaceutical Services Inc
- Tasly Biopharmaceuticals Co Ltd
- Tempero Bio
- Thera Neuropharma Inc
- Theragen Etex Co Ltd
- Theratome Bio Inc
- TikoMed AB
- Tranquis Therapeutics Inc
- Transposon Therapeutics Inc
- Treeway BV
- Treventis Corp
- Triplet Therapeutics Inc
- Ultragenyx Pharmaceutical Inc
- UniQure NV
- Unity Biotechnology Inc
- Vanqua Bio Inc
- Vaxxinity Inc
- VectorY Therapeutics Inc
- Velvio GmbH
- Verge Genomics
- Viridian Therapeutics Inc
- Voronoi Group
- Voyager Therapeutics Inc
- Wave Life Sciences Ltd
- Wren Therapeutics Ltd
- Xalud Therapeutics Inc
- XellSmart Biomedical (Shanghai) Co Ltd
- Xonovo Inc
- Yantai YenePharma Co Ltd
- Yumanity Therapeutics Inc
- Zhittya Genesis Medicine Inc
- ZZ Biotech LLC
